when it counts

Houston startup creates new tech to track hair loss treatment

This startup is making sure every follicle of hair on your head is counted. Photo via myhaircounts.com

A Houston startup has launched its first tech tool to track hair loss using AI and machine learning.

MyHairCounts created a hair density imaging kit and app based on proprietary and patent-pending software. The kit includes a variety of items such as scalp imaging guides, a comb, and gel to help individuals photograph their hair follicles at specified angles. Users then upload these photographs into the app for analyses which are delivered within 48 hours. These analyses inform the user whether or not their hair regrowth treatment is effective.

“Checking your shower or bathroom sink is simply not an accurate way to see if you are losing hair, says Gordon Little, CEO of Awareable Technologies, the parent company of the product. “Anyone who is concerned about losing their hair needs accurate information to evaluate their hair regrowth treatment. Until now, tracking your hair density was impossible.”

Little founded the company in Houston 2017, and the team has grown to 20 people working remotely across the country. The analysis process is completed using AI and machine learning. In order to develop this automation, the web developers fed the system countless images of hair follicles so that it could measure and report on hair growth or loss. According to MyHairCounts, individuals only notice hair loss after hair density has decreased by 20 to 30 percent.

“This product really is unique,” says Kenny Robinson, CMO for MyHairCounts. “If you’re concerned about hair loss, this is the only way a consumer can know whether or not what they are doing is truly working.”

MyHairCounts Hair Density Imaging Kit is available on their website and on Amazon. Currently in the soft launch of their products, they are using this time to work closely with individuals and med spas to review and improve the product prior to their official launch. You can purchase the kit for yourself, but MyHairCounts also offers kits to hairdressers looking to better serve their clients.

Using the kit and the app, individuals or hair stylists can track their own or their clients' hair loss. Image via myhaircounts.com

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted